Table 1.
The clinical trials of drugs which target AR pre-translational alterations in metastasized PCa patients in recent 5 years
| Agents | Target | Additional drugs | Trial phase | Identifier | Start year |
|---|---|---|---|---|---|
| Targeting AR amplification | |||||
| Proxalutamide | AR | None | Phase 1 | NCT02826772 | 2020 |
| AR | None | Phase 2 | NCT05076851 | 2021 | |
| AR | None | Phase 2 | NCT03899467 | 2022 | |
| TQB3720 | AR | None | Phase 1 | NCT04853498 | 2021 |
| SHR3680 | AR | SHR3162 | Phase 1 | NCT02747342 | 2020 |
| AR | SHR3162 | Phase 2 | NCT04102124 | 2020 | |
| AR | Docetaxel | Phase 2 | NCT04603833 | 2021 | |
| Targeting AR mutation | |||||
| Enzalutamide | AR T877A | Flutamide | Phase 4 | NCT02918968 | 2021 |
| Apalutamide | AR T877A | ADT | Phase 3 | NCT02489318 | 2022 |
| Darolutamide | AR F876L | None | Phase 2 | NCT01429064 | 2017 |
| AR W741L | Enzalutamide | Phase 2 | NCT03314324 | 2021 | |
| AR T877A | None | Phase 2 | NCT02933801 | 2022 | |
| TRC253 | AR F877L | None | Phase 1/2 | NCT02987829 | 2021 |
| Targeting AR-V | |||||
| Niclosamide | AR-V7 | Enzalutamide | Phase 1 | NCT03123978 | 2022 |